Publications by authors named "Samuel D Wright"

Claim this Profile
B
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction.
Serge Korjian, Syed Hassan A Kazmi, Gerald Chi, Arzu Kalayci, Jane J Lee, Samuel D Wright

Eur Heart J Cardiovasc Pharmacother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.
Svetlana A Didichenko, Elena Velkoska, Alexei V Navdaev, Brandon H Greene, Shuhui Wang Lorkowski, Samuel D Wright

Arterioscler Thromb Vasc Biol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
Annelie Falkevall, Annika Mehlem, Erika Folestad, Frank Chenfei Ning, Óscar Osorio-Conles, Samuel D Wright

J Hepatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, Gerald Chi, Adam T Phillips, Samuel D Wright

J Cardiovasc Pharmacol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Arzu Kalayci, C Michael Gibson, Paul M Ridker, Samuel D Wright, Bronwyn A Kingwell

Curr Atheroscler Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-administration of CSL112 (apolipoprotein A-I [human]) with atorvastatin and alirocumab is not associated with increased hepatotoxic or toxicokinetic effects in rats.
Andrea Beyerle, Brandon Greene, Barbara Dietrich, Bronwyn A Kingwell, Priya Panjwani, Samuel D Wright

Toxicol Appl Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.
Bo Zheng, Danielle Duffy, Pierluigi Tricoci, Helen Kastrissios, Marc Pfister, Samuel D Wright

Br J Clin Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux.
Alexei V Navdaev, Lorenzo Sborgi, Samuel D Wright, Svetlana A Didichenko

Arterioscler Thromb Vasc Biol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Michael A Tortorici, Danielle Duffy, Rebecca Evans, John Feaster, Andreas Gille, Samuel D Wright

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
Andreas Gille, Danielle Duffy, Michael A Tortorici, Samuel D Wright, Lawrence I Deckelbaum

J Clin Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating HDL levels control hypothalamic astrogliosis via apoA-I.
Anna Götz, Maarit Lehti, Elizabeth Donelan, Cynthia Striese, Sebastian Cucuruz, Samuel D Wright

J Lipid Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
Paul A Gurbel, Udaya S Tantry, Denise D'Andrea, Thomas Chung, John H Alexander, Samuel D Wright

J Thromb Thrombolysis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Andreas Gille, Denise D'Andrea, Michael A Tortorici, Gunter Hartel, Samuel D Wright

Arterioscler Thromb Vasc Biol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.
Alexandre M O Cukier, Patrice Therond, Svetlana A Didichenko, Isabelle Guillas, M John Chapman, Samuel D Wright

Biochim Biophys Acta Mol Cell Biol Lipids· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease.
Mercy R PrabhuDas, Cynthia L Baldwin, Paul L Bollyky, Dawn M E Bowdish, Kurt Drickamer, Samuel D Wright

J Immunol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.
Svetlana A Didichenko, Alexei V Navdaev, Alexandre M O Cukier, Andreas Gille, Patrick Schuetz, Samuel D Wright

Circ Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component.
Eva Herzog, Ingo Pragst, Marcel Waelchli, Andreas Gille, Sabrina Schenk, Samuel D Wright

J Appl Toxicol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Jérôme Robert, Sophie Stukas, Emily Button, Wai Hang Cheng, Michael Lee, Samuel D Wright

Biochim Biophys Acta· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
Sebastian Zimmer, Alena Grebe, Siril S Bakke, Niklas Bode, Bente Halvorsen, Samuel D Wright

Sci Transl Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Pierluigi Tricoci, Denise M D'Andrea, Paul A Gurbel, Zhenling Yao, Marina Cuchel, Samuel D Wright

J Am Heart Assoc· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation.
Nathalie Niyonzima, Eivind O Samstad, Marie H Aune, Liv Ryan, Siril S Bakke, Samuel D Wright

J Immunol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
Andreas Gille, Rachael Easton, Denise D'Andrea, Samuel D Wright, Charles L Shear

Arterioscler Thromb Vasc Biol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
Rachael Easton, Andreas Gille, Denise D'Andrea, Roslyn Davis, Samuel D Wright

J Clin Pharmacol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.
Dominic De Nardo, Larisa I Labzin, Hajime Kono, Reiko Seki, Susanne V Schmidt, Samuel D Wright

Nat Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
Svetlana Diditchenko, Andreas Gille, Ingo Pragst, Dominik Stadler, Marcel Waelchli, Samuel D Wright

Arterioscler Thromb Vasc Biol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis